- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA is reviewing a drug approval application for a condition involving the company GAD.
3 reports, 3 independent
Updated Sep 10
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is reviewing a drug approval application for a condition involving the company GAD.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA reviewing product approval applications for United Therapeutics Corp.1 source
FDA is reviewing drug approval for a condition related to GAD.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA approval expands patient access to therapies for ACCORD.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA and Pfizer are seeking regulatory approval for their products.